SOURCE: Viral Genetics, Inc.

December 14, 2005 09:00 ET

Viral Genetics Updates on South African Clinical Development Initiatives

Follow-Up Stage Completed and Results Expected in Q1-06

AZUSA, CA -- (MARKET WIRE) -- December 14, 2005 -- Viral Genetics, Inc. (OTC BB: VRAL), a drug development company developing a biological therapy for the treatment of HIV infection, today announced that it has completed the follow-up stage of the Phase 3 study of VGV-1 in South Africa. This double-blind, placebo-controlled, randomized, multi-center study of 137 HIV positive patients treated with either VGV-1 or placebo began enrollment in August 2004. The treatment phase of the study was concluded in May 2005, and the final collection of follow-up data on the last patients was completed in November 2005. Upon completion of certain laboratory tests that are now underway, the database will be finalized or "locked." The unblinding and analysis of trial data is expected to begin in January 2006. The Company reiterates its expectation of disclosing initial results of the study analysis in the first quarter of 2006.

If the trial results are positive following unblinding of the study, the Company will be offering VGV-1 therapy to the patients who received placebo in a "crossover" study.

About Viral Genetics, Inc.

Viral Genetics, Inc. is a drug discovery and development company based in southern California developing treatments for infectious disease, autoimmune disease and immunological deficiency through its patented Thymus Nuclear Protein technology. For more information, visit

This news release contains forward-looking statements that involve risks and uncertainties associated with clinical development, regulatory approvals, and other risks described by Viral Genetics, Inc. from time to time in its periodic reports with the Securities and Exchange Commission. VGV-1 and TNP are not approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. While Viral Genetics, Inc. believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including the ability of Viral Genetics, Inc., to obtain adequate financing sufficient to meet its business objectives on reasonable terms and conditions, and therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the forward-looking statements should not be regarded as a representation by the Company or any other person that the objectives and plans of the Company will be achieved.

Contact Information

  • For Information:
    Kathy Lane
    Investor Relations